Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 16, Issue 3-4, Pages 143-146

The Significance of PSA/IGF-1 Ratio in Differentiating Benign Prostate Hyperplasia from Prostate Cancer

G. Koliakos,1 D. Chatzivasiliou,2 Th. Dimopoulos,2 V. Trachana,1 K. Paschalidou,1 V. Galiamoutsas,2 A. Triantos,1 G. Chitas,2 A. Dimopoulos,2 and G. Vlatsas1

1Department of Biological Chemistry, Medical School, Aristotle University of Thessaloniki, Greece
2Urology Clinic, Hospital “Panagia”, Social Security Foundation, Thessaloniki, Greece

Received 8 May 2000; Accepted 20 December 2000

Copyright © 2000 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The importance of insulin-like growth factor 1 (IGF-1) in human serum for the early diagnosis of prostate cancer is controversial. The IGF-1/PSA ratio may improve the performance of prostate specific antigen (PSA) as a prostate cancer marker. IGF-1, along with PSA and free PSA concentration, was measured in the serum of 34 patients with prostate cancer and in 131 patients with benign prostatic hyperplasia (BPH). Although IGF-1 concentration did not significantly differ between the groups, PSA/IGF-1 ratio could clearly distinguish the two groups. In patients with cancer but not in patients with BPH, IGF-1 concentration correlated with PSA and free PSA. The values of PSA and free PSA correlated with each other for both groups. Receivers Operating Curve (ROC) analysis indicated a better sensitivity to specificity ratio for PSA/IGF-1 than for PSA or Free/Total (F/T) PSA.